Hubei Jumpcan Pharmaceutical (600566) H1 2026 earnings summary

Executive summary

• Revenue for H1 2026 was RMB 2.33 billion, down 15.29% year-over-year; net profit attributable to shareholders rose 8.26% to RMB 784 million.

• Gross margin improved as cost controls offset revenue decline; operating cash flow decreased 12.13% year-over-year.

• R&D pipeline advanced with new approvals and clinical progress in innovative drugs; key products maintained market leadership.

• No interim dividend or capital increase from reserves was proposed.

Financial highlights

• Operating income: RMB 2.33 billion (–15.29% YoY); net profit: RMB 784 million (+8.26% YoY).

• Gross margin improved as cost of sales fell 28.52% YoY; sales expenses down 22.68%.

• Basic and diluted EPS: RMB 0.85 (+8.97% YoY); ROE: 5.33% (+0.42pp YoY).

• Net cash from operations: RMB 855 million (–12.13% YoY); total assets: RMB 17.01 billion.

• Non-recurring gains: RMB 188 million, mainly from investment and government grants.

Outlook and guidance

• Company will continue to invest in R&D and expand product pipeline, focusing on pediatric, respiratory, digestive, and gynecological drugs.

• Plans to strengthen digital transformation, supply chain resilience, and multi-channel sales.

• Expects ongoing policy and pricing pressures but aims to mitigate via innovation and cost control.